Literature DB >> 18854264

CK5 is more sensitive than CK5/6 in identifying the "basal-like" phenotype of breast carcinoma.

Rohit Bhargava1, Sushil Beriwal, Kim McManus, David J Dabbs.   

Abstract

Multiple immunohistochemical stains, including cytokeratin (CK)5/6, are used in a panel format to identify "basal-like" carcinomas. We set out to determine the sensitivity and specificity of the CK5 antibody (clone XM26) and compared its expression with that of CK5/6 (clone D5/16B4) in a variety of breast carcinoma cases. The study was performed on 3 breast carcinoma tissue microarrays (TMAs). TMA-1 consisted of 59 consecutive breast carcinoma cases. TMA-2 (n = 16) and TMA-3 (n = 11) consisted of basal-like breast carcinomas previously characterized morphologically and immunohistochemically at our institution. Of the 86 total cases, 20 were positive for CK5 and CK5/6, 14 were positive for CK5 only, and 52 were negative for both. The sensitivity of CK5 for identifying basal-like tumors was 97% compared with 59% for CK5/6. Both antibodies had comparable specificity of more than 95%. For positive cases, the percentage and intensity of staining was much higher with CK5 than with CK5/6 (P = .0001).

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18854264     DOI: 10.1309/AJCP3KFF1LTYWQIY

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  16 in total

1.  Proteomic studies in breast cancer (Review).

Authors:  Xian-Ju Qin; Bruce X Ling
Journal:  Oncol Lett       Date:  2012-01-18       Impact factor: 2.967

2.  Molecular classification predicts survival for breast cancer patients in Vietnam: a single institutional retrospective analysis.

Authors:  Chu Van Nguyen; Quang Tien Nguyen; Ha Thi Ngoc Vu; Khoa Hong Pham; Huyen Thi Phung
Journal:  Int J Clin Exp Pathol       Date:  2021-03-01

3.  Immunostaining for thyroid transcription factor 1, Napsin A, p40, and cytokeratin 5 aids in differential diagnosis of non-small cell lung carcinoma.

Authors:  Satoshi Ikeda; Keishi Naruse; Chigusa Nagata; Masami Kuramochi; Takuya Onuki; Masaharu Inagaki; Keiko Suzuki
Journal:  Oncol Lett       Date:  2015-03-17       Impact factor: 2.967

4.  Prevalence, morphologic features and proliferation indices of breast carcinoma molecular classes using immunohistochemical surrogate markers.

Authors:  Rohit Bhargava; Joan Striebel; Sushil Beriwal; John C Flickinger; Agnieszka Onisko; Gretchen Ahrendt; David J Dabbs
Journal:  Int J Clin Exp Pathol       Date:  2009-02-09

5.  The value of AGR2 and KRT5 as an immunomarker combination in distinguishing lung squamous cell carcinoma from adenocarcinoma.

Authors:  Bo Pan; Zi-Xin Wei; Ju-Xuan Zhang; Xin Li; Qing-Wei Meng; Ying-Yue Cao; Li-Shuang Qi; Yan Yu
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

6.  Keratin expression in breast cancers.

Authors:  Mu-Min Shao; Siu Ki Chan; Alex M C Yu; Christopher C F Lam; Julia Y S Tsang; Philip C W Lui; Bonita K B Law; Puay-Hoon Tan; Gary M Tse
Journal:  Virchows Arch       Date:  2012-08-01       Impact factor: 4.064

7.  Clinical proteomics of breast cancer.

Authors:  Y Baskın; T Yiğitbaşı
Journal:  Curr Genomics       Date:  2010-11       Impact factor: 2.236

8.  A phenotypic mouse model of basaloid breast tumors.

Authors:  Soyoung Kim; Avtar Roopra; Caroline M Alexander
Journal:  PLoS One       Date:  2012-02-09       Impact factor: 3.240

9.  Molecular subtypes, histopathological grade and survival in a historic cohort of breast cancer patients.

Authors:  M J Engstrøm; S Opdahl; A I Hagen; P R Romundstad; L A Akslen; O A Haugen; L J Vatten; A M Bofin
Journal:  Breast Cancer Res Treat       Date:  2013-07-31       Impact factor: 4.872

10.  Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response.

Authors:  Pascal Jézéquel; Delphine Loussouarn; Catherine Guérin-Charbonnel; Loïc Campion; Antoine Vanier; Wilfried Gouraud; Hamza Lasla; Catherine Guette; Isabelle Valo; Véronique Verrièle; Mario Campone
Journal:  Breast Cancer Res       Date:  2015-03-20       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.